Patent Application
20080058420
The present invention relates to pharmaceutical compositions. In particular, the invention relates to a pharmaceutical composition comprising gabapentin. Gabapentin is the common name of 1-aminomethyl-1-cyclohexan-acetic acid, a known drug with anti-epileptic activity, also effective in the treatment of neuropathic pain.
It is known that the formation of lactam with formula:
as a degradation product in the process for preparing and storing gabapentin is a drawback because of the toxicity of the lactam.
In the past, some attempts have been made to contrast the formation of the undesired lactamic byproduct and thus stabilise pharmaceutical compositions containing gabapentin.
The U.S. Pat. No. 6,054,482 in the name of Gödecke AG appears to solve the problem of favouring the conversion of less than 0.2% of gabapentin to the corresponding lactam, in a formulation whose initial lactam content is less than 0.5%, maintained for one year at 25° C. and 60% relative humidity, thanks to a presence of anions of mineral acid below 20 ppm and of excipients that do not promote gabapentin dehydration. The same patent also lists a series of additives to be avoided in the composition because they promote the formation of lactam. They are: modified maize starch, sodium croscarmellose, glycerol behenic acid ester, methacrylic acid co-polymers (type A and C), anion exchange resins, titanium dioxide, silica gcl and PEG with low molecular weight.
On the other hand, U.S. Pat. No. 6,531,509 in the name of Teva Pharmaceuticals Industries Ltd. states that the conditions supposed to assure stability, described in the aforementioned Gödecke AG patent, are technically unnecessary to achieve stability.
According to the Teva patent, not only stable gabapentin compositions can be obtained even when the mineral acid anion content exceeds 20 ppm, but in fact it is possible to use as preferred excipients those excipients that, according to the Gödecke patent, promoted the laetamic degradation of gabapentin.
The patent application No. WO 02/26263 by Sigmapharm describes stable gabapentin compositions containing a stabiliser that comprises a compound able to reduce ionic force, and at least 20 ppm of a mineral acid anion.
The stabilisers belongs to the following classes: volatile alcohols, non-volatile alcohols, non-volatile liquids, water miscible solids or liquids, water immiscible solids or liquids, liquid or solid surfactants, anti-oxidants, ketones or aldehydes.
It is readily apparent that not only the conflicting teachings of the aforementioned prior art are useless in solving the problem of lactam degradation in gabapentin formulations, but they are also likely to generate some confusion in a person skilled in the art.
Therefore, the ability to identify excipients suitable to control the formation of the lactamic impurity should be considered surprising in view both of the difficulties faced in the past in identifying suitable excipients, and of the confusion that actually can be noted in the state of the art with respect to excipient choice.
The present inventors met the need of identifying conditions that are able to control gabapentin structural integrity without increasing its susceptibility to degradation to the corresponding lactamic form.
Therefore, it is a first object of the present invention a stable pharmaceutical composition comprising gabapentin as active ingredient, characterised in that it also comprises a mixture of excipients capable of not promoting the conversion of gabapentin into the corresponding lactamic impurity, which comprises:
According to the present invention, a calcium salt of a weak acid is, preferably, tribasic calcium phosphate.
According to the present invention, a monosaecharidic sugar is, preferably, sorbitol.
According to the present invention, a galactomannan is, preferably, guar rubber.
According to the present invention a polysaccharide derivative is, preferably, alginic acid.
According to the present invention an alginic acid salt is sodium, potassium or calcium alginate, preferably sodium or calcium alginate, more preferably calcium alginate.
According to the present invention, a pectin is, preferably, citrus pectin.
According to the present invention a carrageenan is the kappa, iota, lambda or ksi carrageenan, or a calcium, ammonium or potassium salt thereof, preferably a calcium salt. In particular, a carrageenan is, preferably, the lambda carrageenan or a calcium salt thereof.
Moreover, the excipients listed above, when mixed with gabapentin even in small quantities with respect to the active principle, are able to impart to the resulting mixture some favourable technological properties especially with regard to the sliding property.
This advantageous property can be exploited to facilitate pharmaceutical operations that entail allocating the powders, such as the manufacture of capsules and bags, without using complex technical approaches.
In a preferred aspect of the present invention, a diluting agent is present in a mixture with one or more diluting agents selected from those mentioned above. Preferably, the diluting agents in the mixture are sorbitol and alginic acid.
A particular pharmaceutical composition according to the invention comprises gabapentin as the active ingredient, tribasic calcium phosphate as a sliding agent, hydrogenated castor oil as a lubricant, sorbitol and alginic acid in mixture as diluents. In the pharmaceutical compositions according to the invention, the amount of gabapentin can vary from 50% to 99% of the total by weight of the composition, preferably from 70% to 98% of the total by weight of the composition; the amount of a sliding agent can vary from 0.5% to 5% of the total by weight of the composition, preferably from 1% to 3% of the total by weight of the composition; the amount of a lubricating agent can vary from 0.1% to 8% of the total by weight of the composition, preferably from 0.5% to 6% of the total by weight of the composition; and the amount of a diluting agent can vary from 0% to 50% of the total by weight of the composition, preferably from 0% to 40% of the total by weight of the composition.
The pharmaceutical compositions according to the present invention can be prepared according to the classic technique suggested by the state of the art, i.e. mixing the dry powders of each ingredient in a suitable mixer and the allocation of the mixture by means of a common encapsulating machine.
According to the present invention, a stable pharmaceutical composition containing gabapentin is one in which the content of the corresponding lactamic impurity does not exceed 0.2% by weight of gabapentin, after being maintained for 3 months at the storage conditions of 25° C. with 60% of relative humidity, and/or at 30° C. with 65% of relative humidity.
Some of the pharmaceutical compositions of the invention, evaluated as a representative example, have demonstrated that they meet the aforementioned conditions and they can therefore be considered stable for the purposes of the present invention.
Since, as stated above, the pharmaceutical compositions of the invention can be considered stable, not causing the undesired degradation of the active ingredient, they can be used successfully to prepare the pharmaceutical forms for oral use of gabapentin, in particular in the preparation of capsule, e.g. capsules made of hard gelatine or cellulose.
Therefore, a further object of the present invention is the use of the pharmaceutical composition as described above for the preparation of gabapentin capsules and the capsules that contain said composition.
The better to illustrate, without limiting, the present invention, the following examples are now provided.
In a Turbula Mod. T2F mixer of the company Bachofen (Basil-Switzerland) equipped with a metallic container with a capacity of 2 litres, a mixture of powders constituted by gabapentin and by the appropriate excipients able not to promote the conversion of gabapentin into the corresponding lactamic impurity, is charged for 10 minutes at room temperature at a speed of 10 rpm.
The mixture of powders thus obtained, depending on the amount of ingredients introduced, can have a composition falling within the following values:
gabapentin 50-99% of the total by weight of the composition;
a sliding agent 0.5-5% of the total by weight of the composition;
a lubricating agent 0.1-8% of the total by weight of the composition; and
a diluting agent 0-50% of the total by weight of the composition.
The powders thus obtained are discharged and they are ready to be allocated in capsules.
With the procedure described in Example 1, the following pharmaceutical compositions were prepared. The quantities of the components being expressed in % of the component out of the total by weight of the composition.
Composition 1
Gabapentin 75%
Sorbitol 15%
Alginic acid 4%
Hydrogenated castor oil 5%
Tribasic calcium phosphate 1%
Composition 2
Gabapentin 70%
Fructose 12.5%
Pectin 10%
Carrageenan λ 5%
Glyceryl behenate 0.5%
Tribasic calcium phosphate 2%
Composition 3
Gabapentin 90%
Mannitol 3%
Calcium alginate 1%
Hydrogenated castor oil 3%
Tribasic calcium phosphate 3%
Composition 4
Gabapentin 95%
Tribasic calcium phosphate 4%
Glyceryl behenate 1%
Composition 5
Gabapentin 80%
Xylitol 10%
Erythritol 1%
Maltodextrin 5%
Glyceryl behenate 2%
Tribasic calcium phosphate 2%
Composition 6
Gabapentin 60%
Isomalt 10%
Saccharose 20%
Alginic acid 9%
Hydrogenated castor oil 0.5%
Tribasic calcium phosphate 0.5%
Composition 7
Gabapentin 75%
Dextrose 10%
Guar rubber 7%
Hydrogenated castor oil 6%
Tribasic calcium phosphate 2%
Composition 8
Gabapentin 85%
Maltitol 5%
Tribasic calcium phosphate 2%
Glyceryl behenate 1%
Hydrogenated castor oil 7%
Composition 9
Gabapentin 90%
Sorbitol 3%
Sodium alginate 1%
Glyceryl behenate 2%
Hydrogenated castor oil 1%
Tribasic calcium phosphate 3%
The pharmaceutical compositions of Example 2 were used separately to fill capsules made of hard gelatine and cellulose, obtaining pharmaceutical forms of gabapentin in capsules, by using an IN-CAP Model automatic encapsulating machine by the company Dott. Bonapace (Milan-Italy).
| Number | Date | Country | Kind |
|---|---|---|---|
| MI2004A001447 | Jul 2004 | IT | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/EP05/53473 | 7/19/2005 | WO | 1/17/2007 |
